论文信息 - Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type - 字舞流文

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type

K. Ono | M. Nohgawa | S. Oka

[1] G. Salles,et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data , 2021, Blood advances.

[2] C. Querfeld,et al. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B‐cell lymphoma, leg type , 2019, British Journal of Haematology.

[3] Y. Kwong,et al. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib , 2019, Annals of Hematology.

[4] R. Bouabdallah,et al. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. , 2018, The Journal of investigative dermatology.

[5] W. Choi,et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries , 2015, Oncotarget.

[6] J. Cerhan,et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] R. Dummer,et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. , 2008, Blood.